We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Global leading causes of death
- Cost associated with emerging infections
- Mononegavirales
- Outbreak
- Deployment to DRC
- Laboratory
- Diagnostic lab: timing is everything
- Major Ebola outbreaks
- Relative burden of virus persistence in survivors
- Risks
- What’s new?
- On site real-time sequencing (minion)
- Ebola virus evolution
- Diagnostic on all deceased
- Ebola
- How long does it take to develop a vaccine?
- Vaccine development process (1)
- Vaccine development process (2)
- Treating "first-responders"
Topics Covered
- The burden of infectious diseases
- Controlling infection disease and the effect on economy
- The phylogenetic tree of Mononegavirales that includes Ebola virus
- Outbreak of infectious diseases worldwide
- Outbreak responses and tools that can be deployed to better control outbreak
- Ebola virus outbreaks
- Importance of developing novel vaccines and vaccine development process
- Treating “first-responders” with vaccine against Ebola
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kobinger, G. (2020, February 27). Usage of vaccines and therapeutics in public health emergencies 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 9, 2024, from https://doi.org/10.69645/OGYU9456.Export Citation (RIS)
Publication History
Financial Disclosures
- Consultant of Inovio Inc for their program on Lassa DNA vaccine development (not mentioned in the talk but the DNA platform for Zika is included and Inovio is on 2 of the slides to acknowledge their contribution). I have not received financial compensation yet however it is possible that I will this year or next to a maximum of $5000 USD/year.
Usage of vaccines and therapeutics in public health emergencies 1
Published on February 27, 2020
28 min
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Professor Gary Kobinger.
I'm the Director of the Infectious Disease Center at the University of Laval, Quebec, Canada.
I'm a Professor in the Department of Infectious Disease, Immunology, and Microbiology.
Today's title is the Usage of Vaccines and
Therapeutics in Public Health Emergencies with a focus on the Ebola virus.
In the first part,
I will be covering the burden of infectious diseases and introducing some concepts of
outbreak responses and tools that can be
deployed to better control the outbreak and bring them to an end.
0:37
This slide shows the global leading causes of death worldwide,
and what you can see on the slide is that infectious diseases are
a big proportion of the causes of death in the human population at 26 percent,
which is comparable to cardiovascular diseases,
and is double the numbers of cancer,
which is quite remarkable.
One thing in Western society is
that the awareness of cancer is higher than infectious disease.
Infectious disease is clearly a big burden on public health.
So, on this pop-up coming up,
what you see is from 2002-2015,
the decrease of this burden caused by
infectious disease on the human population in terms of mortality rates.
You see that about 10 million people were
actually saved mainly by 2 interventions,
and that reduced the number of cases.
Those two interventions are something that needed a lot of work,
which is triple therapy to treat HIV infections.
The second one is a very basic approach.
It was to distribute bed nets impregnated with mosquito repellent to prevent malaria,
especially to children less than five years old.
So, an infant who lives where malaria can be quite severe,
is responsible for a high number of deaths to these children, can be protected.